Robert Langer

Robert Langer is an Institute Professor at the Massachusetts Institute of Technology and one of the most cited engineers in history, with more than 1,400 published papers and 1,400 issued and pending patents. Langer's expertise in drug delivery systems, particularly nanoparticle and polymer-based delivery, was critical to Moderna's development of lipid nanoparticle formulations that protect mRNA from degradation and facilitate cellular uptake. Langer had previously founded or co-founded more than 40 biotechnology companies, including Acuson, Momenta Pharmaceuticals, and BIND Therapeutics, giving him experience in translating academic science into commercial products. His decision to join Moderna was driven by the recognition that mRNA represented a new modality for drug delivery that could transform medicine.

Robert Langer has served on Moderna's board of directors since its founding and has been instrumental in guiding the company's scientific strategy and partnerships. His laboratory at MIT continues to conduct foundational research in drug delivery, tissue engineering, and nanotechnology,, the National Medal of Technology and Innovation, and the Charles Stark Draper Prize. His involvement in Moderna provided credibility with investors and scientific collaborators, and his network of academic and industry relationships facilitated partnerships that accelerated the company's development. Langer's continued board service reflects his ongoing commitment to the company's mission of transforming mRNA science into medicines.

Robert Langer was born in 1948 in Albany. Education: Cornell University College of Engineering; Cornell University.